Innova Captab Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab Limited reported its audited consolidated and standalone financial results for Q4 and FY25 on May 19, 2025. Consolidated revenue from operations rose to ₹12,436.76 million in FY25 from ₹10,813.05 million in FY24, a growth of about 15%. Consolidated profit after tax jumped to ₹1,282.58 million from ₹943.45 million, up roughly 36% year-on-year, while EPS improved to ₹22.41 from ₹18.66. On a standalone basis, revenue grew to ₹9,580.61 million and PAT rose to ₹894.70 million. For Q4 alone, consolidated revenue was ₹3,147.41 million versus ₹2,626.34 million a year earlier. Statutory auditors B S R & Co. LLP issued an unmodified (clean) opinion on both sets of results.
Strong double-digit profit growth driven by higher sales and lower finance costs (especially in FY24 comparison) is a positive signal for shareholders. Clean audit opinion and consistent performance support investor confidence, though the stock may react to whether margins continue to expand going forward.